Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2Breast 2Tumor-Agnostic 1Head & Neck 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Bone Metastasis From Solid Tumors 1Bone Metastases From Solid Tumors 1

Interventions

Injections 17Cisplatin 15Carboplatin 15Oxaliplatin 11Gemcitabine 11pembrolizumab 8Capecitabine 8toripalimab 7Paclitaxel 7Etoposide 7Cyclophosphamide 7Pemetrexed 6Irinotecan 6Drug Therapy 6spartalizumab 5fludarabine 5camrelizumab 5Vincristine 5Radiotherapy 5Leucovorin 5tislelizumab 4apatinib 4anlotinib 4Interleukin-2 4Immune Checkpoint Inhibitors 4Granulocyte-Macrophage Colony-Stimulating Factor 4Fluorouracil 4Docetaxel 4Bevacizumab 4tremelimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Denosumab × Other solid neoplasm × Clear all
NCT04859569 2021-06-07

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

Luye Pharma Group Ltd.

Phase 3 Unknown
850 enrolled
Other solid neoplasm

Bone Metastases From Solid Tumors

NCT04494373 2020-08-04

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Unknown
154 enrolled
Other solid neoplasm

Bone Metastasis From Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡